Drugs / VDA-1102
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03538951 | May → Dec 2018 | actinic keratosis | Vidac Pharma | Completed | No outcome recorded |
| Phase 2 | NCT02844777 | Jul 2016 → May 2017 | actinic keratosis | Vidac Pharma | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 13
| Date | Issuer | Release |
|---|---|---|
| 2026-03-03 | Vidac Pharma | Results Vidac Pharma Presents Compassionate Case in Pediatric Brain Cancer at the Eilat Symposium on Pediatric Cancer vidacpharma.com ↗
Vidac Pharma Holdings Plc. (XETRA: T9G | ISIN: GB00BM9XQ619 | WKN: A3DTUQ) announces that the Company presented results from a compassionate use case involving its lead drug candidate, VDA-1102, at the Eilat Symposium on Pediatric Cancer. |
| 2025-09-15 | Vidac Pharma | Regulatory Vidac Pharma Submits Clinical Study Application to EMA for Advanced Actinic Keratosis Lesions vidacpharma.com ↗
The submission reflects a thorough cross-functional effort by Vidac Pharma’s R&D, clinical operations, regulatory, and quality teams, working closely with Forschungsdock CRO GmbH to deliver a complete and scientifically robust dossier. |
| 2025-05-28 | Vidac Pharma | Results Vidac Pharma Reports Exceptional Pharmacokinetics of Almavid™ Drug Candidate in Real-World Clinical study vidacpharma.com ↗
Vidac Pharma, a clinical-stage biopharmaceutical company developing first-in-class cancer therapeutics, today announced promising real-world pharmacokinetics results from the use of its investigational drug Almavid™, a proprietary subcutaneous formulation of VDA 1102 (Tuvatexib), in pediatric brain cancer patients. |
| 2025-03-04 | Vidac Pharma | Results Vidac Pharma Holding PLC Announces Participation in the First Pediatric Brain Tumor Research Meeting vidacpharma.com ↗
As part of a compassionate treatment program for a five-year-old child, Vidac Pharma’s investigational drug VDA-1102 was successfully formulated to cross the blood-brain barrier (BBB) and was detected within the tumor at potentially therapeutic concentrations. |
| 2025-01-02 | Vidac Pharma | Results Vidac Pharma Receives Final Report on Cutaneous T-Cell Lymphoma (CTCL) Clinical Study, Paving the Way for Phase 2-3 Trials vidacpharma.com ↗
Time to Response: VDA-1102 demonstrated rapid efficacy, with responses observed within 8-12 weeks—substantially faster than existing treatments. |
| 2024-03-11 | Vidac Pharma | Regulatory Vidac Pharma secures approval for next phase of clinical study into lead asset into CTCL vidacpharma.com ↗
Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announced it has received approval from the Helsinki Committee of the Beilinson Hospital in Israel to proceed with the second stage of a Phase 2a clinical trial of its lead drug candidate VDA-1102 in Mycosis Fungoides (MF), a form of Cutaneous T-Cell Lymphoma (CTCL). |
| 2024-02-06 | Vidac Pharma | Regulatory Vidac Pharma receives issue notification from US patent office for manufacturing of lead asset VDA-1102 vidacpharma.com ↗ |
| 2024-01-29 | Vidac Pharma | Results Vidac Pharma reports favorable data from Phase 2a interim analysis for its lead asset VDA-1102 in CTCL vidacpharma.com ↗ |
| 2018-12-14 | Vidac Pharma | Results VIDAC PHARMA ANNOUNCES PUBLICATION OF A PEER REVIEWED ARTICLE ON VDA-1102 MECHANISM OF ACTION vidacpharma.com ↗
This peer-reviewed article establishes that VDA-1102’s mechanism of action is blocking the ‘glycolysis metabolic program’ in cancer cells forcing them to undergo programmed cell death. |
| 2017-10-12 | Vidac Pharma | Results VIDAC PHARMA REPORTS POSITIVE RESULTS FROM PHASE 2A PROOF-OF-CONCEPT TRIAL OF VDA-1102 OINTMENT IN ACTINIC KERATOSIS vidacpharma.com ↗
Vidac Pharma reports positive results from Phase 2A Proof-of-concept trial of VDA-1102 OINTMENTin Actinic Keratosis |
| 2016-12-12 | Vidac Pharma | Results VIDAC PHARMA PHASE 2A STUDY OF VDA-1102 IN ACTINIC KERATOSIS MEETS INTERIM ANALYSIS CRITERION vidacpharma.com ↗
Vidac Pharma, a clinical-stage oncology-focused pharmaceutical company, today announced that the ongoing Phase 2 study with VDA-1102 ointment, a potent selective VDAC/HK2 modulator, in actinic keratosis (AK) met a pre-determined interim analysis criterion. |
| 2016-06-30 | Vidac Pharma | Results VIDAC PHARMA COMPLETES PHASE 1A TRIAL OF VDA-1102 OINTMENT vidacpharma.com ↗
The convincing safety and tolerability data from this Phase 1a clinical study serve as solid foundations for our Phase 2 development program. |
| 2015-12-30 | Vidac Pharma | Regulatory Vidac Pharma Announces Filing of IND with U.S. FDA for Development of VDA-1102 for Treatment of Actinic Keratosis vidacpharma.com ↗
“Filing this IND is a transformative milestone for Vidac Pharma as it becomes a clinical stage biopharmaceutical company” |
All press releases naming this drug 20 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VDA-1102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02844777 ↗ |
| Route | Topical | “5% VDA-1102 topical dermal ointment” NCT02844777 ↗ |